Which is the eligible patient to be treated with pioglitazone? The expert view

Pioglitazone has an important role in the treatment of patients with Type 2 diabetes. The drug can help patients to achieve sustained glycemic control and may delay the requirement for insulin. Pioglitazone may provide benefits beyond its effects on glycemia, with data suggesting it may confer anti-...

Full description

Saved in:
Bibliographic Details
Published in:Journal of endocrinological investigation 2011-11, Vol.34 (10), p.781-787
Main Authors: Avogaro, A., Federici, M., Betteridge, J., Bonadonna, R., Campbell, I. W., Schernthaner, G. H., Staels, B., Farinaro, E., Crepaldi, G.
Format: Article
Language:English
Subjects:
Algorithms
Animals
Atherosclerosis - prevention & control
Blood Glucose - drug effects
Cardiotonic Agents - therapeutic use
Diabetes Mellitus, Type 2 - drug therapy
Endocrinology
Humans
Hypoglycemic Agents - therapeutic use
Insulin - therapeutic use
Insulin Resistance
Medicine
Medicine & Public Health
Metabolic Diseases
Opinion
Thiazolidinediones - adverse effects
Thiazolidinediones - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pioglitazone has an important role in the treatment of patients with Type 2 diabetes. The drug can help patients to achieve sustained glycemic control and may delay the requirement for insulin. Pioglitazone may provide benefits beyond its effects on glycemia, with data suggesting it may confer anti-atherosclerotic and cardioprotective properties. Attention should be given to possible side effects relating to class effects of TZD, and selection of appropriate patients to be prescribed pioglitazone will enable optimum benefits to be derived from pioglitazone treatment.
ISSN:0391-4097
1720-8386
DOI:10.1007/BF03346725